LUF7346
SIGMA/SML1927 - ≥98% (HPLC)
Synonym: 2-
CAS Number: 1821638-40-7
Empirical Formula (Hill Notation): C20H15BrN2O3
Molecular Weight: 411.25
Linear Formula: C20H15BrN2O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C20H15BrN2O3/c21-18-6- |
| InChI key | QNWXOXKHLFTJBA-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | O=C(NC1=CC=CN=C1)COC2=CC= |
| solubility | DMSO: 10 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | LUF7346 has the ability to enhance the potassium current (IKr) in a heterologous system. It is found to be highly effective than other human ether-a-go-go-related gene (hERG) activators, such as Rottlerin and NS1643. |
| Biochem/physiol Actions: | LUF7346 is a Kv11.1 (hERG) allosteric modulator that prevents proarrhythmic effects caused by hERG blockers in rat ventricular myocyte cultures. |
| Biochem/physiol Actions: | LUF7346 is a Kv11.1 (hERG) allosteric modulator that prevents proarrhythmic effects caused by hERG blockers in rat ventricular myocyte cultures. LUF7346 reduces Kv11.1 (ERG) affinity toward known Kv11.1 channel blockers dofetilide (Ki for hERG = 4.8 nM without and 12 nM with 10 μM LUF7346) and astemizole (Ki for for hERG = 1.3 nM without and 5.3 nM with 10 μM LUF7346) and effectively suppresses astemizole-induced arrhythmogenic events in a dose-dependent manner among Long-QT syndrome/LQTS (LQT1, JLNS, LQT2) and control isogenic human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). LUF7346 is shown to slow IKr deactivation and positively shifts IKr inactivation among LQTS and control isogenic hiPSC-CMs without affecting KCNQ1/KCNE1-dependent IKs or L-type calcium current ICaL. |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |